| Daily nocturnal hemodialysis--a paradigm shift worthy of disrupting current dialysis practice. | |
| | |
MedLine Citation:
|
PMID: 18779853 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Various strategies have been considered in attempts to improve the outcomes of dialysis patients. Such strategies include increasing dialysis dose, using alternative depuration methods, changing dialysis schedules and focusing on preventing or treating specific co-morbidities and complications. In this Viewpoint, Andreas Pierratos discusses the first three strategies, and concludes that he believes that a paradigm shift, a disruptive change-in the form of daily home nocturnal hemodialysis-is needed to improve dialysis outcomes. |
| | |
Authors:
|
Andreas Pierratos |
Related Documents
:
|
453713 - Malignant melanoma--an overview. 14768383 - Wound management in reptiles. 8432503 - Changes in health and job attitudes of case managers providing intensive services. |
Publication Detail:
|
Type: Journal Article; Review Date: 2008-09-09 |
Journal Detail:
|
Title: Nature clinical practice. Nephrology Volume: 4 ISSN: 1745-8331 ISO Abbreviation: - Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-10-28 Completed Date: 2009-01-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101261800 Medline TA: Nat Clin Pract Nephrol Country: England |
Other Details:
|
Languages: eng Pagination: 602-3 Citation Subset: IM |
Affiliation:
|
A Humber River Regional Hospital, University of Toronto, Weston, ON, Canada. a.pierratos@utoronto.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Appointments and Schedules Circadian Rhythm Humans Kidney Failure, Chronic / mortality, therapy Peritoneal Dialysis / methods*, mortality Quality of Life* Randomized Controlled Trials as Topic Renal Dialysis / methods*, mortality Risk Assessment Sensitivity and Specificity Survival Analysis |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Facts and controversies in the use of trastuzumab in the adjuvant setting.
Next Document: A wearable artificial kidney: dream or reality?